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Heterozygous RFX6 protein truncating variants are
associated with MODY with reduced penetrance
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Finding new causes of monogenic diabetes helps understand glycaemic regulation in humans.
To find novel genetic causes of maturity-onset diabetes of the young (MODY), we sequenced
MODY cases with unknown aetiology and compared variant frequencies to large public
databases. From 36 European patients, we identify two probands with novel RFX6 hetero-
zygous nonsense variants. RFX6 protein truncating variants are enriched in the MODY
discovery cohort compared to the European control population within ExAC (odds ratio= 131,
P= 1 × 10−4). We find similar results in non-Finnish European (n= 348, odds ratio = 43,
P= 5 × 10−5) and Finnish (n= 80, odds ratio = 22, P= 1 × 10−6) replication cohorts. RFX6
heterozygotes have reduced penetrance of diabetes compared to common HNF1A and
HNF4A-MODY mutations (27, 70 and 55% at 25 years of age, respectively). The hyper-
glycaemia results from beta-cell dysfunction and is associated with lower fasting and
stimulated gastric inhibitory polypeptide (GIP) levels. Our study demonstrates that hetero-
zygous RFX6 protein truncating variants are associated with MODY with reduced penetrance.
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F inding the genetic cause of rare familial diabetes (monogenicdiabetes) provides new biological insights into humanpancreas development and function, as well as potentially
novel therapeutic targets with important treatment implications1.
Maturity-onset diabetes of the young (MODY) is monogenic
diabetes resulting from beta-cell dysfunction which usually
present before the age of 25 years in non-obese patients who are
non-insulin-dependent and have an autosomal dominant
inheritance of diabetes2. Mutations in HNF1A, HNF4A and GCK
are the commonest causes of MODY responsible for ~60% of
MODY aetiology1.
There has been limited recent success in finding new MODY
genes. WFS1 heterozygous variants and loss-of-function variants
in the APPL1 gene were shown to be a rare cause of MODY3, 4.
The reason for this limited success is the difficulty of distin-
guishing monogenic diabetes patients from those with type 1
diabetes5, 6, or from the increasing number of patients with early-
onset type 2 diabetes due to rising rates of obesity. Another
important reason is the lack of large pedigrees with an autosomal
dominant pattern of inheritance of diabetes which would allow
classical linkage analysis to be performed and which was used to
discover the most common forms of MODY such as GCK,
HNF1A and HNF4A7–10.
Rare-variant association testing is an important step to confirm
the pathogenicity of novel variants in monogenic disease11. Rare-
variant association testing particularly for comparing the
frequency of novel protein-truncating variants (PTVs) in
monogenic cases with unknown aetiology to the frequency in
large control cohorts is now possible because of the availability of
resources such as ExAC – a database of protein coding variants in
large control populations12. This allows burden testing of the
frequency of novel or rare coding variants in diseases of interest
and a comparison to rates in controls to identify new genetic
causes of monogenic disease.
In this study, we have undertaken next-generation sequencing
of MODY cases with unknown aetiology and compared the
frequency of PTVs to large publicly available control cohorts to
identify new MODY genes. Our study shows that heterozygous
RFX6 PTVs are associated with MODY.
Results
Heterozygous RFX6 PTVs in MODY with unknown aetiology.
To identify patients with novel heterozygous PTVs, we first
assessed 38 European (non-Finnish) probands with a strong
MODY-like phenotype who did not have mutations in the
common MODY genes (GCK, HNF1A, HNF4A) by Sanger
sequencing (Supplementary Table 1). To exclude the other
known/less common causes of monogenic diabetes, these patients
underwent comprehensive targeted-next generation sequencing
(NGS) for all 29 known monogenic diabetes genes, including
genes for neonatal diabetes, MODY and mitochondrial diabetes,
lipodystrophy or other forms of syndromic diabetes13 (Supple-
mentary Table 2). We identified two probands with mutations in
the known MODY gene HNF1B13, 14. The analysis of
heterozygous PTVs in the 29 genes on the targeted panel iden-
tified two unrelated probands with a novel heterozygous nonsense
variant in Regulatory Factor X 6 (RFX6) (Family 1 - p.Leu292Ter,
Family 2 - p.Lys351Ter) (Table 1, Fig. 1 and Supplementary
Table 3). We did not identify any rare (<1%) missense RFX6
variants in this cohort. RFX6 was part of the targeted sequencing
panel because recessive RFX6 variants (missense and/or protein-
truncating) are a known cause of syndromic neonatal diabetes15,
but heterozygotes were not previously known to have any
phenotype.
RFX6 PTVs are enriched in a MODY discovery cohort. We next
compared the frequency of RFX6 PTVs in our discovery cohort to
a large control population with whole-exome data from ExAC12.
Neither of the RFX6 variants from the discovery cohort were
present in the 60,706 individuals in ExAC. There were 15
individuals with RFX6 PTVs in the 33,346 ExAC non-Finnish
European control population (Supplementary Table 3). The fre-
quency of the RFX6 PTVs in the MODY discovery cohort was
significantly higher (after accounting for the multiple testing of
29 genes) than the ExAC non-Finnish European control popu-
lation (5.5 vs. 0.045%, odds ratio (OR) 131, 95% confidence
interval (CI) 14-595, P= 1 × 10−4) (Table 1).
RFX6 PTVs are enriched in a MODY replication cohort. To
replicate the findings of our discovery cohort, we then examined
348 non-Finnish European probands who were routinely referred
for MODY genetic testing to the Molecular Genetics Laboratory,
Exeter, UK and in whom the common causes of MODY were
excluded using targeted-NGS assay (Supplementary Table 1). The
analysis of heterozygous PTVs identified four unrelated probands
with two novel RFX6 nonsense variants (p.Gln25Ter, p.Arg377-
Ter) (Supplementary Fig. 1 and Supplementary Table 3). Simi-
larly to the discovery cohort, the MODY replication cohort was
enriched for RFX6 PTVs compared to the ExAC non-Finnish
European control population (1.15 vs. 0.045%, OR= 26, 95% CI
6–82, P= 3 × 10−5) (Supplementary Table 4). This association
was maintained when compared to an independent non-Finnish
European control population with whole-genome sequence data
from gnomAD (http://gnomad.broadinstitute.org) (Table 1 and
Supplementary Table 4). The frequency of RFX6 PTVs in the
gnomAD genome data set (0.027%) is not statistically different to
that in ExAC (0.045%, P= 0.76).
Higher frequency of RFX6 PTVs in Finnish population. Finnish
individuals had ~10-fold higher frequency of RFX6 PTVs
compared to non-Finnish Europeans. The ExAC database
showed a relative abundance of RFX6 PTVs in Finnish Europeans
(15/3305, 0.45%) compared to non-Finnish Europeans
(15/33,346, 0.045%) (Supplementary Table 3). All of the Finnish
individuals in ExAC with RFX6 PTVs had the same variant,
p.His293Leufs. To further validate this finding in a larger
Finnish control population, we analysed RFX6 PTVs in
7040 control individuals from the METSIM study in
Table 1 Frequency of heterozygous RFX6 protein-truncating variants in all study cohorts and control populations
MODY cohorts, frequency of RFX6 PTV Control population, frequency of RFX6 PTV Odds ratio (95% CI) P-value
Non-Finnish European Discovery cohort (n= 2/36), 5.5% ExAC – exomes (n= 15/33,346), 0.045% 131 (14–595) 1 × 10−4
Replication cohort (n= 4/348), 1.15% gnomAD – genomes (n= 2/7508), 0.027% 43 (6–483) 5 × 10−5
Finnish European Replication cohort (n= 6/80), 7.5% METSIM-exomes (n= 26/7040), 0.37% 22 (7–56) 1 × 10−6
Meta-analysis Heterogeneity (χ2= 2.73 (d.f.= 2), P= 0.256) 34 (15–80) 1 × 10−16
Cl, confidence interval; MODY, maturity-onset diabetes of the young; PTV, protein-truncating variant
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Eastern Finland16. There were 26 individuals with RFX6 PTVs
in this cohort and all had the p.His293Leufs variant. The
frequency of p.His293Leufs was not significantly different
from the ExAC Finnish population frequency (0.37 vs. 0.45%,
P= 0.63) (Supplementary Table 3). The METSIM study has
contributed to the ExAC Finnish cohort, so to prevent
duplication we used the data from the larger METSIM study for
further analysis12.
Enrichment of RFX6 p.His293Leufs in Finnish MODY
patients. To assess whether the p.His293Leufs variant is
associated with MODY in Finnish patients, we genotyped the
RFX6 p.His293Leufs variant in 80 Finnish probands who were
routinely referred for MODY genetic testing to Genome Center of
Eastern Finland, University of Eastern Finland and did not have
mutations in the most common MODY genes (GCK, HNF1A,
HNF4A and HNF1B) (Supplementary Table 1). We identified six
probands with the p.His293Leufs variant. The frequency of this
variant was significantly higher in the Finnish MODY cohort
compared to the METSIM controls (7.5 vs. 0.37%, OR= 22, 95%
CI 7–56, P= 1 × 10−6) (Table 1). The meta-analysis of the three
independent case–control analyses confirmed the strong
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Fig. 1 Extended pedigree of non-Finnish European patients identified in the discovery cohort. a Pedigree of family 1 that were identified with heterozygous
RFX6 variant (NM_173560.3:c.875-T>G,p.Leu292Ter) from the discovery cohort. b Pedigree of family 2 from the discovery cohort with heterozygous
RFX6 variant (NM_173560.3:c.1051-A> T, -p.Lys351Ter). Genotype is shown underneath each symbol; M and N denote mutant and wild-type alleles,
respectively. Directly below the genotype is the age of diabetes onset in years, duration in years, BMI and treatment at study entry. Squares represent male
family members, and circles represent female members. Black-filled symbols denote patients with diabetes. An arrow denotes the proband in the family.
OHA, oral hypoglycaemic agents. *age at recruitment. One of the daughters of patient III.1 in family 2 had a history of gestational diabetes
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association of RFX6 PTVs with MODY in the study cohorts (OR
= 34, 95% CI 15–80, P= 1 × 10−16) (Table 1).
Enrichment of RFX6 PTVs is not due to technical artefacts. To
ensure that the association we observed is not due to differences
in sequencing technologies or analysis pipelines between cases
and controls, we performed a series of sensitivity analyses. This
included comparisons to additional whole exome, whole genome
and in-house control cohorts and an analysis that removed exon
1 which was the least well covered exon in ExAC. These sensi-
tivity analyses (Supplementary Table 4) show that results are
consistent for all these analyses.
RFX6 PTVs co-segregate with diabetes. To further assess the
causality of RFX6 PTVs, we conducted a co-segregation analysis in
families with genetic data available on more than three affected
individuals. We had only one family (family 1) with >3 affected
individuals with genetic data (Fig. 1)17. The analysis showed
that the RFX6 variant p.Leu292Ter co-segregated in 9 out of 10
individuals with diabetes (LOD score= 0.65, P= 0.04). One indi-
vidual without the RFX6 variant had diabetes which is likely to be a
phenocopy of type 2 diabetes considering the large pedigree, age of
diagnosis and obesity (51 years, body mass index (BMI)
30 kg/m2). There were two family members with an RFX6 variant
but with normal HbA1c level at the time of study (18 and 57 years)
suggesting that RFX6 PTVs may have reduced penetrance.
Reduced penetrance of diabetes with RFX6 PTVs. To assess the
penetrance of RFX6 PTVs for diabetes compared to common
causes of MODY, we combined data for all six non-Finnish
European proband families. There were 18 RFX6 heterozygotes of
whom five had not developed diabetes at study entry. 27% (95%
CI 11–58) developed diabetes by the age of 25 years and 78%
(95% CI 55–95) by 51 years (Fig. 2). Two out of six probands did
not have affected parents at study entry (Supplementary Fig. 1).
The penetrance of diabetes for RFX6 heterozygotes was sub-
stantially lower compared to pathogenic variants of HNF1A (70%,
95% CI 67–72 by the age of 25 years and 97%, 95% CI 96–98 by
50 years) and moderately lower than pathogenic variants of
HNF4A (55%, 95% CI 50–60 by the age of 25 years and 91%, 95%
CI 88–94 by 50 years) (Fig. 2). Similar to non-Finnish European
proband families, the Finnish RFX6 p.His293Leufs variant also
showed reduced penetrance in Finnish families (Supplementary
Fig. 2). In two previously reported families of neonatal diabetes
children with homozygous p.Arg181Gln RFX615, 18 or RFX6 p.
His293Leufs19, the genetic information available on RFX6 het-
erozygous family members was also suggestive of reduced pene-
trance of diabetes (Supplementary Figs 2 and 3).
RFX6 PTVs are not enriched in type 2 diabetes. The reduced
penetrance and later age of onset of diabetes with RFX6 PTVs
raised the possibility that these variants may be associated with
type 2 diabetes. To assess this, we used freely available data from
the Type 2 Diabetes Knowledge Portal which contains whole-
exome data on type 2 diabetes patients20. Burden testing of RFX6
PTVs for exome sequencing data from 8373 type 2 diabetes cases
and 8466 controls showed no significant association with type 2
diabetes (0.14 vs. 0.083%, OR= 1.79, 95% CI 0.7–4.57, P= 0.22)20
(Supplementary Table 3).
Phenotype of RFX6 heterozygotes with diabetes. We assessed
the diabetes phenotype in 27 RFX6 heterozygote individuals with
diabetes. The clinical features are shown in Table 2. The median
age at diagnosis of diabetes was 32 years (IQR 24–46, range 13–64
years) and median BMI of 25.1 kg/m2 (IQR 23–28). After a
median 10 years (IQR 5–22) of diabetes 69% of patients were
treated with insulin but there was significant endogenous insulin
present in 24/25 patients at recruitment. There was no history of
sulphonylurea sensitivity and they did not have islet auto-
antibodies (GADA/IA2-Ab). All patients had isolated diabetes
and there were no reports of the other features of homozygous
RFX6 mutations, such as duodenal or gall bladder atresia.
RFX6 haploinsufficiency is associated with reduced GIP. RFX6
is a transcription factor and has been shown to increase expres-
sion and secretion of gastric inhibitory polypeptide (GIP) in
mouse enteroendocrine K-cells21. We therefore measured the
incretin hormone GIP in 17 RFX6 heterozygotes (eight with
diabetes) and compared to 26 controls (two with diabetes). The
fasting GIP was markedly lower in RFX6 heterozygotes compared
to controls (16 (10–24) vs. 49 (28–65) pg ml−1, P= 1.2 × 10−5).
Fasting glucagon-like peptide-1 (GLP-1) levels were not different
in both groups (23 (12.5–32) vs. 24 (14–32) pg ml−1, P= 0.98). To
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Fig. 2 Penetrance of diabetes in people with MODY. Heterozygous RFX6
PTV (n= 18), pathogenic HNF1A variant (n= 1265) or HNF4A variant (n=
427)
Table 2 Clinical characteristics of patients with RFX6-MODY
Characteristic (n= 27)
Age at diagnosis (years), median (IQR) 32 (24–46)
Duration of diabetes, median (IQR) 10 (5–22)
Female, n (%) 22 (81%)
BMI (kg/m2), median (IQR) 25.1 (23–28) n= 22
Initial treatment, n (%)
Diet 4 (15%)
Oral hypoglycaemic agents 14 (54%)
Insulin 5 (19%)
Insulin + oral hypoglycaemic agents 3 (12%)
Current treatment, n (%)
Diet 2 (8%)
Oral hypoglycaemic agents 6 (23%)
Insulin 12 (46%)
Insulin + oral hypoglycaemic agents 6 (23%)
HbA1c at recruitment, mmol/mol, median (IQR) 51 (45–70) n= 22
Significant endogenous insulin at recruitmenta,
n (%)
24 (96%) n= 25
BMI, body mass index; IQR, interquartile range; MODY, maturity-onset diabetes of the young
aNon-insulin treated or insulin treated with urine/blood random C-peptide> 200 pmol/l at
recruitment
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remove potential confounding factors, we compared the OGTT
data for the 11 Finnish RFX6 p.His293Leufs heterozygotes
without diabetes to five matched (age, sex and BMI) controls
for each heterozygote from the PPP-Botnia Study (Fig. 3 and
Supplementary Table 6). This confirmed that both fasting
and 120 min stimulated GIP was reduced (18.3 vs. 48.9 pg ml−1,
P= 8 × 10−3, 167 vs. 241 pg ml−1, P= 0.029, respectively). In
addition, the non-diabetic heterozygotes had higher fasting glu-
cose (5.5 vs. 5.1 mmol l−1, P= 0.02) with a similar fasting insulin
level suggesting a beta-cell defect (Supplementary Table 6).
Discussion
Heterozygous RFX6 PTVs are associated with MODY. We iden-
tified RFX6 PTVs predicted to be pathogenic11, 19 in unrelated
MODY patients in whom the known causes of monogenic dia-
betes had been excluded. These variants were enriched in Finnish
and non-Finnish European MODY probands but were rare in the
control cohorts and in patients with type 2 diabetes. We observed
co-segregation within pedigrees albeit with reduced penetrance.
Finally, these variants are likely to have a functional effect due to
nonsense-mediated decay causing haploinsufficiency12, 22. This is
further supported by the studies that showed that the homozygous
RFX6 PTVs cause neonatal diabetes15, 23, 24. Among unknown
MODY cases, RFX6 PTVs were responsible for 7.5% Finnish cases
compared to only ~1% of non-Finnish European cases.
Large-scale control cohorts such as ExAC in combination with
next-generation sequencing of well-characterised cases is a useful
strategy for identifying new causes of monogenic disease. The
large ExAC database provides sufficient power for reliable burden
testing of rare variants in monogenic disease12 without the need
for large pedigrees or linkage analysis. RFX6 PTVs were highly
enriched in both discovery and replication cohorts compared to
control cohorts, supporting their pathogenicity. The ExAC data-
base has been very useful in identifying benign variants because of
an unusually high frequency in the population compared to fre-
quency of the disease in question11, 12, 25. However, caution is
required for reduced penetrance variants as their frequency can be
higher than estimated disease frequency in the general population.
RFX6 PTVs are an example where the reduced penetrance
explains the higher frequency in control cohorts compared to the
estimated frequency of MODY (0.01%) in the general popula-
tion26. In addition, our study highlights the importance of
population specific control and disease cohorts. The frequency of
RFX6 PTVs is ~10-fold higher in the Finnish population com-
pared to non-Finnish populations due to the well-documented
bottleneck in population genetics27, 28. This observation is not
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Fig. 3 Phenotypic characteristics of the Finnish RFX6 p.His293Leufs heterozygotes without diabetes. Figure shows the phenotypic characteristics at fasting
and during an oral glucose tolerance test (OGTT) of the Finnish RFX6 p.His293Leufs heterozygotes without diabetes (filled symbols; n= 11) compared
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restricted to RFX6 alone. It has been shown that the Finnish
population has an overall higher burden of genome-wide PTVs
(0.5–5%) in many genes compared to non-Finnish Europeans, and
some of these have been associated with disease27–29.
RFX6 PTVs are associated with reduced penetrance
MODY. This reduced penetrance explains the lack of complete
co-segregation in the RFX6 pedigrees. It also clarifies why
diabetes was only reported in the parents or grandparents
(obligate heterozygous for functional RFX6 variants) in seven
out of the 12 published recessive RFX6 neonatal diabetes
pedigrees15, 18, 24, 30–36. The lack of enrichment of RFX6 PTVs in
type 2 diabetes patients compared to controls further supports
their association with reduced penetrance MODY rather than
type 2 diabetes. Further studies are needed to understand the
mechanism of reduced penetrance of diabetes in RFX6 hetero-
zygotes. It could be due to a combination of factors, such as
expression patterns of normal alleles, epigenetic modifications
and rare or common genetic variant modifiers37.
There are differences as well as similarities between RFX6-
MODY and HNF1A/HNF4A-MODY. In contrast to HNF1A and
HNF4A-MODY patients, RFX6-MODY patients do not show
enhanced sensitivity to sulphonylureas38. All patients with
HNF1A/HNF4A-MODY have significant endogenous insulin 3–5
years post diagnosis39. RFX6-MODY patients showed a similar
pattern, except for one patient who did not have detectable
endogenous insulin. Similar to HNF1A/HNF4A-MODY6, 38,
RFX6-MODY patients lack islet autoantibodies and have isolated
diabetes. This suggests that persistent C-peptide, lack of islet
autoantibodies and parental history of diabetes, which are
currently used to distinguish common forms of MODY from type
1 diabetes, can also be used to identify RFX6-MODY. However, a
similar strategy will not help to distinguish late onset RFX6-
MODY from type 2 diabetes.
Our study supports the role of RFX6 in the adult human
pancreas. RFX6 is from a family of transcription factors that
contains winged-helix DNA-binding domains15. RFX6 is
expressed almost exclusively in pancreatic islets, small intestine
and colon15. It acts downstream of NGN3, regulates islet cell
differentiation and the development of the endocrine pancreas15.
The homozygous RFX6 missense and PTVs cause syndromic
neonatal diabetes (gall bladder aplasia, gut atresia and diabetes)15.
RFX6 whole-body null mice show phenotypes consistent with
human disease and die soon after birth, but the heterozygous
whole-body RFX6 mouse has not been reported to develop
diabetes15. This is not surprising considering the lack of pheno-
type in heterozygous null mice of HNF1A and HNF1B40. Inter-
estingly, the defect in glucose-induced insulin secretion was
present in models that are more akin to haploinsufficiency of
RFX6 in adult humans33, 41. 80% depletion of RFX6 protein in the
adult mouse pancreas in vivo as well as in human beta cells
in vitro showed that this defect was due to reduced expression of
ABCC8, GCK and Ca2+ channels in beta cells and disruption of
Ca2+-mediated insulin secretion33,41. These data support the
role of RFX6 in the physiology of adult beta cells. This along
with evidence of impaired of beta-cell function (requirement
of insulin to maintain euglycaemia, one patient with C-peptide
<200 pmol l−1, lower C-peptide in heterozygotes with diabetes
compared to without diabetes (Supplementary Fig. 4)), suggest
that insulin deficiency is the cause of diabetes in these patients.
Incretins are gut hormones released in response to meals that
potentiate glucose-stimulated insulin secretion. GIP is secreted
from enteroendocrine K-cells in the duodenum and upper
jejunum and mediates the bulk of the incretin effect in healthy
individuals42. The secretion of GIP and GLP-1 is preserved
in type 2 diabetic patients43, 44 and in patients with other forms
of diabetes, including type 1 diabetes45 and HNF1A-MODY46.
The present identification of GIP deficiency in RFX6 PTV het-
erozygotes is in keeping with the murine data showing that GIP
expression and secretion is regulated by Rfx621, and, importantly,
identifies the first human form of diabetes associated with
decreased GIP secretion.
In conclusion, heterozygous RFX6 PTVs are associated with
reduced penetrance MODY and GIP deficiency.
Methods
Study populations. Discovery MODY cohort: The discovery cohort comprises
38 European probands with strong MODY-like phenotype who did not have
mutations in the three most common MODY genes (GCK, HNF1A and HNF4A)
(Supplementary Table 1). They were diagnosed <25 years of age, non-obese,
had ≥3 generation history of diabetes, non-insulin treated or insulin treated with
C-peptide > 200 pmol l−1 (if available) and lacked islet autoantibodies.
Non-Finnish European replication MODY cohort: The replication cohort was
derived from 469 non-Finnish European routine MODY diagnostic referrals to the
Molecular Genetic Laboratory, Exeter, UK. A monogenic aetiology in a known
monogenic diabetes gene was identified in 121 patients and the remaining 348
patients with unknown aetiology comprised the replication cohort (Supplementary
Table 1).
Finnish-European replication MODY cohort: This cohort consisted of 80
patients who were routinely referred for MODY diagnostic testing to the Genome
Center of Eastern Finland, University of eastern Finland in whom no mutation was
found in the common MODY genes (GCK, HNF1A, HNF1B and HNF4A) when
assessed by Sanger sequencing (Supplementary Table 1). These 80 patients
comprise 78% of the total MODY X Finnish cohort.
Finnish-European control cohort: Individuals of this cohort were part of the
METSIM study (n= 7040). They were all males aged 45–70 years, randomly
selected from the population register of the Kuopio town, Eastern Finland16.
Cohort of people with pathogenic HNF1A and HNF4A variants: This cohort
included probands and their family members referred to the Molecular Genetics
Laboratory, Exeter, UK for MODY genetic testing and were identified to have a
pathogenic HNF1A (n= 1265) or HNF4A (n= 427) variant.
Phenotypic characterisation of RFX6 heterozygotes: In total, we had 47 RFX6
heterozygotes of whom 27 had diabetes. 29/47 were part of the discovery and
replication cohorts. 18/47 were identified separately or had been previously
reported18, 23 (Supplementary Fig. 2 – Families 3–5, Supplementary Fig. 3). The
clinical features of RFX6-MODY were based on 27 individuals with diabetes. 13/27
were part of the discovery and non-Finnish replication cohort (Fig. 1,
Supplementary Fig. 1 – Families 1–6). 9/27 individuals were from the Finnish
replication cohort (5/9 individuals were from Supplementary Fig. 2 – Families 1
and 2, Pedigrees were not available for 4/9 individuals). In addition to this, we
included five diabetic individuals that were identified separately. This comprised a
single Finnish individual (Supplementary Fig. 2 – Family 3) and four individuals
from a previously reported family from Belgium (Supplementary Fig. 3)18.
Incretin analysis: We completed physiological studies on 25/47 RFX6
heterozygotes in whom 10 had diabetes. 7/25 had fasting blood sample analysis and
18/25 had 75 g oral glucose tolerance test (OGTT). We used 27 (12 family and 15
unrelated) controls that included two individuals with diabetes for an initial
comparison of fasting GIP/GLP-1. RFX6 heterozygotes had similar age (38 (34–58)
vs. 40 (30–61) years, P= 0.70), sex (female 64 vs. 56% P= 0.58) and BMI
(24 (23–29) vs. 27 (24–30) kg/m2, P= 0.27) distribution as the 27 controls. Fasting
GIP/GLP-1 levels were available on 17/25 RFX6 heterozygotes and 26/27 controls.
Out of 25 individuals who were assessed for GIP/GLP-1 analysis, 16 Finnish
individuals (five with diabetes, 11 without diabetes) participated in the
FINNMODY Study (www.botnia-study.org/finnmody, recruiting patients with
MODY-like diabetes and their relatives in Finland). It is linked to the population-
based PPP-Botnia study and the participants had been subjected to standardised
OGTT, sample collection and detailed biochemical analysis following the study
protocol of the PPP-Botnia study. Therefore, to remove any potential confounding
factors, we compared the phenotypic characteristics of these 11 RFX6 p.
His293Leufs heterozygotes without diabetes to five controls for each heterozygote
from the PPP-Botnia study matched for age, sex and BMI. None of the controls
had the RFX6 p.His293Leufs variant.
PPP-Botnia Study: The Prevalence, Prediction and Prevention of diabetes
(PPP)–Botnia Study is a population-based study in Western Finland aiming at
obtaining accurate estimates of prevalence and risk factors for type 2 diabetes,
impaired glucose tolerance, impaired fasting glucose and the metabolic syndrome
in the adult population (Isomaa). Altogether 5208 individuals randomly recruited
from the national Finnish Population Registry participated in the baseline study in
2004–2008 (representing 6–7% of the population), and 3870 (77%) individuals
participated in the follow-up study in 2011–2014. The participants with fasting
plasma glucose< 10 mmol l−1participated in an 75 g OGTT with venous samples
taken at 0, 30, 120 min for plasma glucose and serum insulin; at 0 and 120 min for
serum C-peptide, GIP and GLP-1. The participants gave their written informed
consent and the study protocol was approved by the Ethics Committee of Helsinki
University Hospital, Finland.
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Plasma glucose was analysed using the Hemocue Glucose System (HemoCue
AB, Ängelholm, Sweden). Serum insulin was measured by an AutoDelfia
fluoroimmunometric assay (PerkinElmer, Waltham, Massachusetts, US) and serum
C-peptide by Cobas e411 electrochemiluminometric immunoanalysis (Roche,
Mannheim, Germany). Serum GIP was analysed using Millipore’s Human GIP
Total ELISA (Merck, Darmstadt, Germany; catalogue # EZHGIP-54K), which has
100% cross-reactivity to both human GIP (1–42) and GIP (3–42). Serum total
plasma GLP-1 concentrations, which detects both intact GLP-1 and GLP-1
(9–36 amide), were determined using Millipore’s radioimmunoassay (Merck,
Darmstadt, Germany; catalogue #GLP1T-36HK). Serum total cholesterol, high-
density lipoprotein and triglyceride concentrations were measured first on a Cobas
Mira analyser (Hoffman LaRoche, Basel, Switzerland) and low-density lipoprotein
cholesterol concentrations were calculated using the Friedewald formula, and since
January 2006 with an enzymatic method (Konelab 60i analyser; Thermo Electron
Oy, Vantaa, Finland).
The RFX6 p.His293Leufs variant was genotyped in 5187 individuals by the
Kompetitive Allele Specific PCR genotyping system (KASPTM) on Demand
(KOD) assay according to the manufacturer’s testing conditions including six
positive control samples identified by direct sequencing (LGC Hoddesdon, Herts,
UK). Two out of 5180 participants had RFX6 p.His293Leufs (the genotyping failed
in 7), which was confirmed by direct sequencing.
DNA analysis. Targeted next-generation sequencing: The analysis of all known
monogenic diabetes genes in European cohorts was conducted using targeted-
NGS13. The panel included 29 genes in which variants are known to cause
monogenic neonatal diabetes, MODY, mitochondrial diabetes, lipodystrophy or
other forms of syndromic diabetes13 (Supplementary Table 2). The RFX6 PTVs
identified by targeted-NGS were confirmed using Sanger sequencing. The
essential splice site, nonsense and frameshift variants excluding the last exon were
considered PTVs in this study12, 22. The targeted-NGS assay covered 100% bases of
the RFX6 coding region with >10× read depth for all the samples.
Sanger sequencing: Genomic DNA was extracted from whole blood using
standard procedures and the coding region and intron/exon boundaries of the
RFX6 gene were amplified by PCR. Amplicons were sequenced using the Big Dye
Terminator Cycler Sequencing Kit v3.1 (Applied Biosystems, Warrington, UK)
according to manufacturer’s instructions and reactions were analysed on an ABI
3730 Capillary sequencer (Applied Biosystems, Warrington, UK). Sequences were
compared with the reference sequences (NM_173560.3) using Mutation Surveyor
v3.24 software (So Genetics, State College, PA, USA).
The Finnish-European MODY cohort was analysed for p.His293Leufs variant
using Sanger sequencing as described above. Family co-segregation analysis was
performed in available family members using a Sanger sequencing assay for the
specific RFX6 variant identified in that family. DNA analysis of the METSIM study
has been described before23.
Statistical analysis. Fisher’s exact test was used to compare the frequency of RFX6
PTVs. The threshold P-value for association was 1 × 10−3 as there were 29 genes on
the panel (0.05/29). The penetrance of diabetes was assessed using survival time
analysis method. The statistical analysis was conducted using Stata 14 (StataCorp,
Texas, USA). The comparison of RFX6 heterozygotes to PPP-Botnia controls were
conducted using R (3.3.2) with packages for the data manipulation (dplyr) and
visualization (ggplot2). Continuous variables were compared with Mann–Whitney
U-test and categorical variables with chi-squared test. Single point non-parametric
linkage analyses were performed using MERLIN 1.1.247. The Z-score was
converted into a LOD score by use of the Kong and Cox exponential model
implemented in MERLIN47, 48.
Ethics. Informed consent was obtained from all subjects. The UK study is
approved by the North Wales Research Ethics Committee. The FINNMODY/PPP-
Botnia study is approved by the Research Ethics committee for Medicine of the
Helsinki University Hospital.
Data availability. The majority of data used in this study are publically available
and can be accessed via the studies cited in the text. Considering issues of patient
confidentiality and restrictions in IRB permissions, other original data are available
through specific request.
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